MARKET

BLCM

BLCM

Bellicum Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.770
+0.270
+6.00%
Closed 16:00 03/27 EDT
OPEN
4.490
PREV CLOSE
4.500
HIGH
4.860
LOW
4.290
VOLUME
98.38K
TURNOVER
--
52 WEEK HIGH
40.50
52 WEEK LOW
3.320
MARKET CAP
24.08M
P/E (TTM)
-0.0199
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BLCM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BLCM stock price target is 17.25 with a high estimate of 25.00 and a low estimate of 9.00.

EPS

BLCM News

More
  • Mid-Afternoon Market Update: Dow Surges Over 800 Points; Amyris Shares Slide
  • Benzinga · 03/13 18:31
  • Mid-Day Market Update: Citi Trends Rises After Q4 Results; Inovio Pharmaceuticals Shares Plunge
  • Benzinga · 03/13 18:11
  • SOHO, TLRY, CPLG and BLCM among midday movers
  • Seeking Alpha - Article · 03/13 16:44
  • Raymond James Maintains Outperform on Bellicum Pharmaceuticals, Lowers Price Target to $17
  • Benzinga · 03/13 11:18

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About BLCM

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
More

Webull offers kinds of Bellicum Pharmaceuticals Inc stock information, including NASDAQ:BLCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLCM stock news, and many more online research tools to help you make informed decisions.